RecruitingACTRN12615000042549

Detection of Individuals with Preclinical, Prodromal and Mild Alzheimer's Disease for Therapeutic Trials.

Detection of Individuals with Preclinical, Prodromal and Mild Alzheimer's Disease optimizing the use of cognitive and blood biomarker findings to increase the rate of amyloid scan positive subjects using Amyloid and Fluorodeoxyglucose Positron Emission Tomography (FDG PET) imaging for Therapeutic trials.


Sponsor

Professor Chris Rowe

Enrollment

450 participants

Start Date

Dec 17, 2014

Study Type

Interventional

Conditions

Summary

This study aims to use recent advances in PET scanning techniques, in particular Amyloid scanning to assist in the detection of Preclinical, Prodromal and Mild Alzheimer's disease.


Eligibility

Sex: Both males and femalesMin Age: 50 YearssMax Age: 85 Yearss

Plain Language Summary

Simplified for easier understanding

This study is looking for people who may have very early or mild Alzheimer's disease. Researchers want to use a special brain scan called an amyloid PET scan to help find people who might benefit from future treatments. This scan can detect a protein buildup in the brain that is linked to Alzheimer's disease before serious memory problems develop. You may be eligible if: - You are between 50 and 85 years old - You have mild memory or thinking problems (mild cognitive impairment) or mild Alzheimer's disease - You have completed at least 6 years of school - You can speak and understand English well enough for memory testing - You can hear and see well enough for the tests - You are able to have an MRI scan - Your MMSE (memory test) score is 20 or above - You are interested in taking part in research You may NOT be eligible if: - You have another brain or nervous system disease besides Alzheimer's - You have a serious mental illness - You have been diagnosed with cancer in the last 5 years (not counting skin cancer or early-stage prostate cancer) - You have a problem with drug or alcohol use - You cannot have an MRI scan (for example, due to a metal implant) Talk to your doctor about whether this trial might be right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

Cognitive assessment will be performed at visits one and four lasting approximately one hour. Blood biomarker sampling will occur at visit 4. The Amyloid PET scan will be done at visit two and invo

Cognitive assessment will be performed at visits one and four lasting approximately one hour. Blood biomarker sampling will occur at visit 4. The Amyloid PET scan will be done at visit two and involves intravenous injection of 200 +/-10%MBq of (18F)Nav4694. A 20-minute scan will be acquired starting at 50 minutes post injection. Where MRI Brain scan results with a 3D sequence from within the past six months are not available, an MRI will be done at visit 2 or visit 3. An FDG PET scan will be done at visit three using an intravenous injection of 185 +/-10% of (18F)FDG. A 15-minute scan will be acquired starting at 30 minutes post injection.


Locations(1)

Austin Health - Austin Hospital - Heidelberg

VIC, Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12615000042549


Related Trials